AIDS reviews最新文献

Pulmonary arterial hypertension (PAH) occurs more frequently in patients with HIV infection than in general population. The predictive value of HIV-related factors and traditional cardiovascular factors with PAH is inconsistent across studies. The objective is to determine the roles of HIV-related risk factors and traditional cardiovascular risk factors in the development of PAH in adults with HIV. We searched Pubmed/Medline, Embase, Web of Science, and Google Scholar to identify studies published between January 1, 2000 and February 23, 2021 on risk factors associated with PAH among people living with HIV (PLWH). Ten studies were included for final analysis. PLWH with PAH had higher mean age (weighted mean difference [WMD] = 2.27, 95% confidence interval [CI] 0.31 ~ 4.24), and lower mean CD4 cell count (WMD = -95.8, 95% CI -153.41 ~ -38.2). Meanwhile, they were more likely to have detectable viral load (odds ratio [OR] = 1.36, 95% CI 1.16 ~ 1.60), to accompany arterial hypertension (OR = 2.02, 95% CI 1.51 ~ 2.71) and less likely to receive antiretroviral therapy (ART) (OR = 0.84, 95% CI 0.72 ~ 0.99). Besides, more intravenous drug users were observed in HIV-infected adults with PAH (OR = 2.25, 95% CI 1.51 ~ 3.33). HIV infection itself and ART impact PAH in two opposite ways. Traditional cardiovascular factors such as arterial hypertension, and older age are also important to the development of PAH. Screening HIV-related factors and traditional cardiovascular factors may help to target and manage patients at risk.

HIV-1 infection usually progresses to AIDS within 10 years in antiretroviral therapy untreated individuals, but there is a group of infected individuals, known as controllers, who maintain low plasma HIV-1 RNA levels and normal CD4+ T-cell counts for many years. Evidence suggests that the mechanisms of viral control in these individuals are heterogeneous. In this review, we highlight the viral and host factors, particularly host immunological and immunogenetic factors that are associated with controller status. Despite the broad heterogeneity within controllers, there is compelling evidence that cytotoxic CD8+ T lymphocyte responses act as the main driver of control in the majority of these individuals, especially in those with protective HLA-I alleles. Further investigation of controllers without protective HLA-I alleles is required as it seems that this subset exhibits more durable control of HIV-1 disease progression. Understanding the immune defense mechanisms in controllers provides hope for harnessing these responses in the general population, either for protective or therapeutic vaccines or to achieve a functional cure in infected individuals.

Timely HIV diagnosis is critical to minimizing transmission events. We sought to estimate the meantime from HIV infection to diagnosis and its temporal trend among people with HIV. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a search of MEDLINE, Embase, and Google Scholar, supplemented by a hand search of bibliographies of articles, was conducted. Study information and outcome measures of time from HIV infection to diagnosis were synthesized. Random-effects metaanalyses were performed. The search identified 12 articles from 4541 unduplicated citations. Studies were conducted in the UK (k = 3), US (k = 3), France (k = 2), Australia (k = 1), Switzerland (k = 1), Netherlands (k = 1), and China (k = 1). The pooled meantime from HIV infection to diagnosis was 3.00 years (95% confidence interval: 2.16-3.84). From 1996 to 2002, meantime reduced from 4.68 to 2.66 years. Subsequently, it increased to 3.20 years in 2003 and remained relatively stable until 2015. In sub-group meta-analyses, men who have sex with men (MSM) had a meantime of 2.62 years (1.91-3.34), while for heterosexuals and people who inject drugs, it was 5.00 (4.15-5.86) and 4.98 (3.97-5.98) years, respectively. In the high- and upper-middle-income countries included in this study, persons live with undiagnosed HIV for about 3 year before being diagnosed. This period is shorter for MSM relative to people with infections attributable to other risk factors.

Liver-related diseases are associated with the high levels of morbidity and mortality in people living with HIV. Between 13% and 18% of all-cause mortality in HIV-infected patients involves a liver-related damage, this being one of the main causes of death not related to acquired immunodeficiency syndrome (AIDS). People living with HIV, even when the disease is under control, are more likely to develop pathologies and complications of a liver-related origin than the general population, both due to common causes such as alcoholism, non-alcoholic fatty liver disease, hepatic viral infections and ageing, in addition to specific HIV-related processes such as antiretroviral treatment toxicity and liver damage inherent to HIV infection. On the other hand, some antiretroviral drugs may have a beneficial effect in reversing liver fibrosis in patients with HIV and chronic liver disease. This paper reviews the main risk factors associated with liver disease in people living with HIV and the role of antiretroviral therapy (ART) in this disease.

Tobacco smoking undermines the effectiveness of antiretroviral therapy (ART) among people living with HIV/AIDS (PLWHA) and potentially associates with other health problems. This study aimed to analyze the growth and content of research on smoking among PLWHA on Web of Science Database. Co-occurrence analysis and Jaccard's' similarity index calculation were performed to identify and visualize networks of countries collaboration, keywords co-occurrence, and research topics. Exploratory factor analysis was applied to the abstracts' contents to uncover research domains and landscapes. The number of publications increased by 14.55% annually in the period of 1991-2017, with 74% of total papers published within 2007-2017. A wide range of topics have been covered, notably co-morbidities, interventions on smoking abstinence and cessation, and the enforcing relationship of smoking cessation with antiretroviral treatment adherence. A shortage of studies on smoking among PLWHA in low- and middle-income countries, limited collaborations between countries outside of close geographical proximity and a lack of discussion on local contexts and psychosocial factors were found. Smoking among PLWHA has been being studied more extensively in recent years, enhancing our knowledge and awareness of the significant and specific effects smoking have on PLWHA, which, in turn, assisting the proposals and implementations of suitable solutions. However, more efforts should be made to examine and understand contextualized aspects, including culture and beliefs specific to each nation or smaller sub-population within a country, especially those currently under-researched, as well as psycho-behavioral factors to implement more effective interventions to reduce smoking among PLWHA.

The prevalence of obesity has increased dramatically in recent decades worldwide. An increase in the prevalence of obesity has also been observed among people living with HIV (PLHIV) in high and low incomes countries. Antiretroviral therapy (ART), by controlling the viral load (VL) and restoring cellular immunity, has improved the health status and life expectancy in PLHIV. However, the risk of developing non-AIDS events (NAEs) remains higher than the general population. Therefore, specific attention is given to managing risk factors associated with NAEs during the follow-up of PLHIV, including obesity. Factors related to weight gain in PLHIV include demographic factors, HIV disease-related factors, and ART-associated factors. In naive PLHIV, weight gain after the initiation of ART is expected. The weight gains observed are generally not severe even if there appear to be risk factors such as the advanced stage of disease (low CD4 cells count and high VL), female sex, black race, and taking integrase strand transfer inhibitors (INSTI) associated or not with tenofovir alafenamide fumarate (TAF). The role of each antiretroviral drug per-se remains to clarify. As INSTI ± TAF has been associated with significant weight gain, further research is needed to identify the individual-level factors predictive of weight gain, the mechanisms of ART-associated weight gain and the clinical relevance of this weight gain. As PLHIV survive longer on effective ART, the prevention and management of NAEs will remain a challenge for healthcare providers.